


PHARMACEUTICAL 2022

Alzamend Neuro Inc. Rank 407 of 466





PHARMACEUTICAL 2022

Alzamend Neuro Inc. Rank 407 of 466

The relative strengths and weaknesses of Alzamend Neuro Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alzamend Neuro Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 20% points. The greatest weakness of Alzamend Neuro Inc. is the variable Net Income, reducing the Economic Capital Ratio by 171% points.

The company's Economic Capital Ratio, given in the ranking table, is -83%, being 161% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	2,913
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	900
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-95
Other Revenues	0
Property and Equipment	0
Research and Development	1,311
Selling, General and Administrative Expense	3,641

Output Variable	Value in 1000 USD
Assets	2,913
Liabilities	900
Expenses	4,952
Revenues	0
Stockholders Equity	2,013
Net Income	-5,047
Comprehensive Net Income	-5,047
Economic Capital Ratio	-83%

